Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib

Anaplastic lymphoma kinase (ALK) rearrangement is an oncogene targeted with approved drugs second to epidermal growth factor receptor (EGFR) in lung cancer. Crizotinib was developed and introduced into clinical practice rapidly and successfully after the discovery of ALK rearrangement in non-small-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Fei-Yu, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427450/
https://www.ncbi.nlm.nih.gov/pubmed/25999733
http://dx.doi.org/10.2147/OTT.S64664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427450/
https://www.ncbi.nlm.nih.gov/pubmed/25999733
http://dx.doi.org/10.2147/OTT.S64664

Ejemplares similares